NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status (Descending) |
---|---|---|---|---|---|---|---|---|---|---|---|
47335-0082-50 | 47335-0082 | Doxorubicin Hydrochloride | LIPODOX | 2.0 mg/mL | Chemotherapy | Antitumor Antibiotic | Anthracycline | Intravenous | Feb. 9, 2012 | May 29, 2015 | In Use |
47335-0083-50 | 47335-0083 | Doxorubicin Hydrochloride | Lipodox 50 | 2.0 mg/mL | Chemotherapy | Antitumor Antibiotic | Anthracycline | Intravenous | Feb. 9, 2012 | May 29, 2015 | In Use |
47335-0176-40 | 47335-0176 | Oxaliplatin | Oxaliplatin | 50.0 mg/10mL | Chemotherapy | Alkylating Agent | Platinum Compound | Intravenous | Aug. 19, 2009 | In Use | |
47335-0178-40 | 47335-0178 | Oxaliplatin | Oxaliplatin | 100.0 mg/20mL | Chemotherapy | Alkylating Agent | Platinum Compound | Intravenous | Aug. 19, 2009 | In Use | |
47335-0284-40 | 47335-0284 | Carboplatin | Carboplatin | 10.0 mg/mL | Chemotherapy | Alkylating Agent | Platinum Compound | Intravenous | March 3, 2014 | In Use | |
50090-0294-09 | 50090-0294 | METHOTREXATE | Methotrexate | 2.5 mg/1 | Chemotherapy | Antimetabolite | Folic Acid Analog | Oral | June 29, 2016 | Jan. 31, 2021 | In Use |
50090-2345-04 | 50090-2345 | Methotrexate, Methotrexate sodium | Methotrexate | 2.5 mg/1 | Chemotherapy | Antimetabolite | Folic Acid Analog | Oral | April 25, 2016 | July 31, 2018 | In Use |
50090-2345-09 | 50090-2345 | Methotrexate, Methotrexate sodium | Methotrexate | 2.5 mg/1 | Chemotherapy | Antimetabolite | Folic Acid Analog | Oral | April 8, 2016 | In Use | |
50268-0154-13 | 50268-0154 | Capecitabine | Capecitabine | 500.0 mg/1 | Chemotherapy | Antimetabolite | Pyrimidine Analog | Oral | March 12, 2018 | In Use | |
50268-0763-11 | 50268-0763 | Temozolomide | Temozolomide | 140.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | March 23, 2017 | July 31, 2021 | In Use |
50268-0763-12 | 50268-0763 | Temozolomide | Temozolomide | 140.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | March 23, 2017 | July 31, 2021 | In Use |
50742-0405-10 | 50742-0405 | Oxaliplatin | Oxaliplatin | 50.0 mg/10mL | Chemotherapy | Alkylating Agent | Platinum Compound | Intravenous | Oct. 29, 2018 | In Use | |
50742-0406-20 | 50742-0406 | Oxaliplatin | Oxaliplatin | 100.0 mg/20mL | Chemotherapy | Alkylating Agent | Platinum Compound | Intravenous | Oct. 29, 2018 | In Use | |
51808-0119-01 | 51808-0119 | I 131 Mini | I 131 Mini | 500.0 mCi/1 | Chemotherapy | Radiopharmaceutical | Iodine 131 | Oral | May 23, 2012 | In Use | |
51808-0128-01 | 51808-0128 | P32 Sodium Phosphate | P32 Sodium Phosphate | 10.0 mCi/4mL | Chemotherapy | Radiopharmaceutical | Phosphorus 32 | Intravenous | June 19, 2012 | In Use | |
51862-0084-14 | 51862-0084 | Temozolomide | Temozolomide | 20.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Oct. 10, 2016 | March 31, 2019 | In Use |
51862-0084-51 | 51862-0084 | Temozolomide | Temozolomide | 20.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Oct. 10, 2016 | March 31, 2019 | In Use |
51862-0086-14 | 51862-0086 | Temozolomide | Temozolomide | 140.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Oct. 10, 2016 | March 31, 2019 | In Use |
51862-0086-51 | 51862-0086 | Temozolomide | Temozolomide | 140.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Oct. 10, 2016 | March 31, 2019 | In Use |
52549-4118-02 | 52549-4118 | Fluorouracil | Fluorouracil | 50.0 mg/g | Chemotherapy | Antimetabolite | Pyrimidine Analog | Topical | March 5, 2010 | In Use | |
52549-4118-05 | 52549-4118 | Fluorouracil | Fluorouracil | 50.0 mg/g | Chemotherapy | Antimetabolite | Pyrimidine Analog | Topical | March 5, 2010 | In Use | |
52549-4118-06 | 52549-4118 | Fluorouracil | Fluorouracil | 50.0 mg/g | Chemotherapy | Antimetabolite | Pyrimidine Analog | Topical | March 5, 2010 | In Use | |
53808-0411-01 | 53808-0411 | Capecitabine | Xeloda | 500.0 mg/1 | Chemotherapy | Antimetabolite | Pyrimidine Analog | Oral | July 1, 2009 | In Use | |
53964-0001-00 | 53964-0001 | Thiotepa | Tepadina | 15.0 mg/1 | Chemotherapy | Alkylating Agent | Nitrogen Mustard /Ethylenimine | Intracavitary, Intravenous, Intravesical | Jan. 26, 2017 | April 18, 2017 | In Use |
53964-0001-01 | 53964-0001 | Thiotepa | Tepadina | 15.0 mg/1 | Chemotherapy | Alkylating Agent | Nitrogen Mustard /Ethylenimine | Intracavitary, Intravenous, Intravesical | Jan. 26, 2017 | Aug. 1, 2018 | In Use |
Found 10,000 results in 7 milliseconds — Export these results